Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
CAMBRIDGE, Mass. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the closing of its
View HTML
Toggle Summary UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the pricing of its
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced that it is commencing an
View HTML
Toggle Summary Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
CAMBRIDGE, Mass. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281
Full data shows safety, tolerability and proof-of-mechanism in healthy volunteers CAMBRIDGE, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the publication of results from its Phase 1 study of M281 in healthy volunteers in the online edition
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a corporate update. “We recently highlighted our pipeline of novel drug candidates for immune-mediated
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)
CAMBRIDGE, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc. , providing license rights for the global launch of M923, Momenta’s proposed biosimilar to HUMIRA.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will present at the Stifel 2018 Healthcare Conference. The presentation is scheduled for Tuesday, November 13, 2018 at 10:15 A.M.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the third quarter ended September 30, 2018 and provide a corporate update before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals to Host R&D Day on October 11, 2018
CAMBRIDGE, Mass. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)  today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018 beginning at 8:30 am ET . The event is being held in New York, NY .
View HTML